Hunting Hill Global Capital’s Amedisys AMED Stock Holding History

Hunting Hill Global Capital’s Portfolio AMED Stock Details AMED Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-2,100	Closed	-$203K	–	95
2024 Q3	$203K	Buy	+2,100	New	+$205K	0.19%	58

Other funds holding AMED

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return

PCM

Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return

UOC

UBS O'Connor Chicago, Illinois $3.38B AUM 63.08% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

AAM

Alpine Associates Management Palm Beach, Florida $1.7B AUM 97.55% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

DKCM

Davidson Kempner Capital Management New York $7.33B AUM 56.47% 1-Year Est. Return

Hunting Hill Global Capital's AMED Position: Q3 2024 in Review

Hunting Hill Global Capital sold out of Amedisys (AMED) in Q3 2024, closing a stake of 714 shares — an estimated $69.7K sold.

Hunting Hill Global Capital first reported a position in AMED in Q4 2023 and held it in 3 quarters. The position peaked at $721K in Q4 2023. 286 funds tracked by Wall St. Rank hold AMED as of Q3 2024.

Hunting Hill Global Capital reported no remaining Amedisys position as of Q3 2024 after selling out during the quarter.
Hunting Hill Global Capital sold 714 Amedisys shares in Q3 2024, an estimated $69.7K.
Hunting Hill Global Capital first reported a position in Amedisys in Q4 2023 and held it in 3 quarters.
Hunting Hill Global Capital's Amedisys position peaked at $721K in Q4 2023.
286 funds tracked by Wall St. Rank held Amedisys as of Q3 2024.

Based on Hunting Hill Global Capital's 13F filing for Q3 2024, filed 14 Nov 2024.